Oramed Oral Insulin Fails to Meet Goal in Type 2 Diabetes Oramed Oral Insulin Fails to Meet Goal in Type 2 Diabetes

Top-line results from phase 3 trial of ORMD-0801 show that the oral insulin product didn ' t meet the phase 3 trial ' s endpoints for change from baseline hemoglobin A1c at 26 weeks.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news